European Companies Search Engine
EU funding (€4,021,969): INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition. Hor 28 Aug 2019 EU Research and Innovation programme "Horizon"
Overview
Text
INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.
New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pharmacology (SP) aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. Especially, cardiovascular (CV) toxicity is problematic, as it is the most prevalent reason for failure during preclinical development. Moreover, CV toxicity remains a key reason for drug attrition during clinical development and beyond. This indicates current SP screens fail to detect a number of (late-onset) functional or structural CV toxicities. Additionally, SP uses a significant number of laboratory animals, thereby creating opportunities for a better implementation of the 3Rs. The vision of INSPIRE is to advance and “inspire” SP by exploring new technological capabilities (WP1), addressing emerging CV concerns (WP2) and delivering new validated solutions for CV safety screening (WP3). To this end, INSPIRE unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a European training platform for 15 Early Stage Researchers (ESRs). Key innovative aspects of INSPIRE include: i) in vitro humanized cardiomyocytes assays, ii) unparalleled in vivo hardware/software solutions, iii) in silico predictions of haemodynamics, iv) mass spectroscopy imaging of drug exposure, v) exploration of mechanisms of late-onset CV toxicity, as observed in cardio-oncology, and vi) early integration of feedback from industry and regulators. Overall, INSPIRE constitutes a multidisciplinary and intersectoral training programme (WP4) with a balanced combination of hands-on research training, intersectoral secondments, local courses and network-wide events on scientific and transferable skills, enabling future R&I collaborations. Hence, INSPIRE will equip the future generation of SP scientists with a wide range of scientific knowledge and the ability to adapt to a dynamic ever-changing industry.
Funded Companies:
| Company name | Funding amount |
| Boehringer Ingelheim Pharma GmbH & Co. KG | €252,788 |
| Institut National de Recherche en Informatique et Automatique | €274,802 |
| Ncardia B.V. | €0.00 |
| Ncardia Services B.V. | €265,620 |
| Notocord Systems | €549,604 |
| The University of Nottingham | €606,345 |
| TSE Systems GmbH | €252,788 |
| UCB Biopharma | €256,320 |
| Universiteit Antwerpen | €768,960 |
| Universiteit Maastricht | €531,240 |
| Weizmann Institute OF Science | €263,501 |
Source: https://cordis.europa.eu/project/id/858070
The filing refers to a past date, and does not necessarily reflect the current state.
